Chemoresistance and targeted therapies in ovarian and endometrial cancers

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
cyclophosphamide 3 endocrinologydiseasesdrugs
endometrial carcinoma 2 endocrinologydiseases
everolimus 12 endocrinologydiseasesdrugs
megestrol 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
cyclophosphamide 9373 Some other chemotherapeutics drugs can also be helpful and used in gynecological cancers including cyclophosphamide (an alkylating agent), gemcitabine (a nucleoside analog), topotecan (a topoisomerase-I inhibitor) or
cyclophosphamide 38828 versus 35% for the sensitive group [[195]]. A second study also tested Veliparib in combination with cyclophosphamide , an alkylating agent, in a study group of 72 women with BRCA mutated ovarian cancer. No significant
cyclophosphamide 79203 tested in a phase II trial with 10 patients with recurrent ovarian cancer, pre-treated with low-dose cyclophosphamide to improve the immunogenicity of the vaccine. They observed a higher number of IFN-γ-producing T cells
everolimus 62306 adenocarcinomas developed accompanied by ascites and peritoneal dissemination. Treating these mice with everolimus alone reduced tumor burden by 84% and ascites and peritoneal dissemination were detected in only 21%
everolimus 62506 in only 21% of the treated mice versus 74% in the placebo-treated animals [[252]]. They also tested everolimus alone and in combination with cisplatin against ovarian cancer both in vitro and in vivo. Using ovarian
everolimus 62660 against ovarian cancer both in vitro and in vivo. Using ovarian cancer cell lines, they found out that everolimus was efficient for inhibiting cell proliferation and when combined with cisplatin, enhanced apoptosis.
everolimus 62968 growth, decrease of ascites and increased treatment efficiency when combined with cisplatin). Noteworthy, everolimus was efficient only in cells with high AKT/mTOR activity [[253]]. These pre-clinical findings were promising
everolimus 63185 promising for the treatment of ovarian cancers. In endometrial cancer, phase II trials have been done using everolimus . One of these, tested everolimus in patients with recurrent endometrial cancer that have previously
everolimus 63218 cancers. In endometrial cancer, phase II trials have been done using everolimus. One of these, tested everolimus in patients with recurrent endometrial cancer that have previously received chemotherapy. After treatment,
everolimus 63491 rate of 22% (CBR; sum of CR, PR and SD) [[254]]. They also performed another phase II trial testing everolimus in combination with letrozole, an aromatase inhibitor, with 35 patients with advanced endometrial cancer.
everolimus 63651 inhibitor, with 35 patients with advanced endometrial cancer. Using hormonal therapy in combination with everolimus increased the CBR, as well as the addition of CR and PR to the results, to 40% indicating a high benefit,
everolimus 63832 results, to 40% indicating a high benefit, considerable for therapy [[255]]. Another phase II trial tested everolimus alone in 44 patients with advanced endometrial cancer (2/3 previously received chemotherapy). After
everolimus 64457 optimal therapies. It is also worth noting that these two compounds inhibiting mTOR (temsirolimus and everolimus ) tested in clinics only inhibit the mTORC1 complex. The mTORC2 complex is involved in the phosphorylation
everolimus 71403 letrozole [[277]]. Another phase II study tested letrozole in combination with the clinical mTor inhibitor everolimus in 35 women with advanced recurrent endometrial cancer. The results were very interesting with 11 CR,
everolimus 71566 cancer. The results were very interesting with 11 CR, 2 PR and 1 SD [[255]]. Their previous study using everolimus alone had a CBR of 21% and only SD [[254]]. The addition of letrozole increased the CBR to 40%, as well
megestrol 60592 ORR prior chemotherapy; 19% ORR without prior chemotherapy). This study also concluded that combining megestrol acetate (a steroidal progestin), tamoxifen and temsirolimus did not improve the treatment efficiency
Select Disease Character Offset Disease Term Instance
endometrial carcinoma 12105 treated with cisplatin [[39]]. Concerning endometrial cancer, copper-transporter ATP7B overexpression in endometrial carcinoma is also related to cisplatin resistance and indicate an unfavorable outcome for patients [[40]].DNA
endometrial carcinoma 49693 cancer [[219]]. Pilaralisib has been used in a phase II study in 67 patients with advanced or recurrent endometrial carcinoma . The ORR was minimal and only two patients had CR and two other patients had PR. No association was

You must be authorized to submit a review.